🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,838 results for “SP” Clear

  1. Propofol

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Urinary Surgery

    approved small molecule completed

    1 trial

  2. Propofol

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nausea and Vomiting

    approved small molecule completed

    1 trial

  3. Prothrombin Complex Concentrate, Human

    The First People's Hospital of Lianyungang

    Cardiac Surgical Procedures

    approved small molecule active

    1 trial

  4. Proton Pump Inhibitors

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Upper Gastrointestinal Hemorrhage

    approved small molecule active

    1 trial

  5. Pulse Sequence

    Aspire Biopharma Holdings

    Atrial Fibrillation

    approved other completed

    1 trial

  6. Qianjin Capsule of Gynaecology

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pelvic Inflammatory Diseases

    approved small molecule active

    1 trial

  7. Qizhitongluo Capsule

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Ischemic Stroke

    approved small molecule completed

    1 trial

  8. Quadrivalent Influenza Vaccine (Split Virion), inactivated

    Sinovac Research and Development Co.,

    Seasonal Influenza

    approved mab completed

    1 trial

  9. Quick-Acting Heart Reliever

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Coronary Artery Stenosis

    approved small molecule completed

    1 trial

  10. RO7034067, Evrysdi 0.75 mg/mL powder for oral solution

    Hoffmann-La Roche

    Spinal Muscular Atrophy (SMA)

    approved small molecule active

    1 trial

  11. ROSUVASTATIN AND EZETIMIBE , BEMPEDOIC ACID , ROSUVASTATIN AND EZETIMIBE , ATORVASTATIN AND AMLODIPINE

    The George Institute

    CHRONIC INFLAMMATORY RHEUMATIC DISEASE: rheumatoid arthritis or psoriatic arthritis or axial spondyloarthritis or systemic lupus erythematosus

    approved small molecule active

    1 trial

  12. Rabbit ATG, (Genzyme)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Aplastic Anemia

    approved small molecule active

    1 trial

  13. Rabipur Pulver und Lösungsmittel zur Herstellung einer Injektionslösung in einer Fertigspritze Tollwut-Impfstoff (inaktiviert), RABIPUR, poudre et solvant pour solution injectable en seringue préremplie. Vaccin rabique (inactivé)., Rabipur poeder en oplosmiddel voor oplossing voor injectie in een voorgevulde spuit.Rabiësvaccin (geïnactiveerd).

    The George Institute

    rabies pre-exposure prophylaxis

    approved small molecule active

    1 trial

  14. Raltitrexed

    The First People's Hospital of Lianyungang

    Head and Neck Squamous Cell Carcinoma

    approved small molecule active

    1 trial

  15. Rapamune 1 mg coated tablets, MYCOPHENOLATE MOFETIL

    The George Institute

    End-stage kidney disease in Type 1 diabetes, SIROLIMUS VERSUS MYCOPHENOLATE MOFETIL IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION TO EVALUATE THE RISK OF HERNIA

    approved small molecule active

    1 trial

  16. Realgar-Indigo Naturalis Formulation Combined with Anlotinib

    The First People's Hospital of Lianyungang

    Platinum-resistant Ovarian Cancer (PROC)

    approved small molecule active

    1 trial

  17. Recaticimab

    The First People's Hospital of Lianyungang

    STEMI - ST Elevation Myocardial Infarction

    approved small molecule active

    1 trial

  18. Recaticimab and Statin

    The First People's Hospital of Lianyungang

    Intracranial Atherosclerosis

    approved small molecule active

    1 trial

  19. Recombinant Human Adenovirus Type 5 injection

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma

    approved small molecule active

    1 trial

  20. Recombinant Staphylokinase

    The First People's Hospital of Lianyungang

    ST-segment Elevation Myocardial Infarction (STEMI)

    approved small molecule completed

    1 trial

  21. Recombinant Staphylokinase

    The First People's Hospital of Lianyungang

    Acute Myocardial Infarction

    approved small molecule completed

    1 trial

  22. Recombinant human growth hormone

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Achondroplasia

    approved small molecule active

    1 trial

  23. Recombinant human growth hormone (r-hGH)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Dwarfism, Pituitary

    approved small molecule completed

    1 trial

  24. Recombinant staphylokinase

    The First People's Hospital of Lianyungang

    ST Elevation Myocardial Infarction

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources